FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, non-randomized study in subjects with histologically
confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who
have not received prior systemic therapy for metastatic disease.